mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Garcia-Beltran, Wilfredo F; St Denis, Kerri J; Hoelzemer, Angelique; Lam, Evan C; Nitido, Adam D; Sheehan, Maegan L; Berrios, Cristhian; Ofoman, Onosereme; Chang, Christina C; Hauser, Blake M; Feldman, Jared; Roederer, Alex L; Gregory, David J; Poznansky, Mark C; Schmidt, Aaron G; Iafrate, A John; Naranbhai, Vivek; Balazs, Alejandro B

Garcia-Beltran, Wilfredo F; St Denis, Kerri J; Hoelzemer, Angelique; Lam, Evan C; Nitido, Adam D; Sheehan, Maegan L; Berrios, Cristhian; Ofoman, Onosereme; Chang, Christina C; Hauser, Blake M; Feldman, Jared; Roederer, Alex L; Gregory, David J; Poznansky, Mark C; Schmidt, Aaron G; Iafrate, A John; Naranbhai, Vivek; Balazs, Alejandro B.

Afiliação

Garcia-Beltran WF; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: wgarciabeltran@mgh.harvard.edu.
St Denis KJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Hoelzemer A; First Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Site Hamburg-Lübeck-Borstel-Riems, Germany; Research Department Virus Immunology, Leibniz Institute for Experimental Virology, H
Lam EC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Nitido AD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
Sheehan ML; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Berrios C; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Ofoman O; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Chang CC; Alfred Hospital, Central Clinical School, Monash University, Victoria 3181, Australia; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.
Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
Roederer AL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
Gregory DJ; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Pediatric Infectious Disease, Massachusetts General Hospital for Children, Boston, MA 02114, USA.
Poznansky MC; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Naranbhai V; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Balazs AB; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.

Cell ; 185(3): 457-466.e4, 2022 02 03.

Article em En | MEDLINE | ID: mdl-34995482

RESUMO

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that received their primary series recently (<3 months), distantly (6-12 months), or an additional "booster" dose, while accounting for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinees. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron, only 4-6-fold lower than wild type, suggesting enhanced cross-reactivity of neutralizing antibody responses. In addition, we find that Omicron pseudovirus infects more efficiently than other variants tested. Overall, this study highlights the importance of additional mRNA doses to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

Palavras-chave

COVID-19; Delta; Omicron; SARS-CoV-2; breadth; infectivity; neutralizing antibodies; spike; vaccination; variants

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google